Healthcare & Life Sciences
Altos Labs
Altos Labs is the most well-funded longevity biotech startup, having raised more than $3 billion to date from prominent backers including Jeff Bezos, Arch Venture Partners founder Robert Nelson, Yuri Milner and Palantir cofounder Joe Lonsdale, researching cellular reprogramming to reverse aspects of biological aging. The company, valued at $5 billion as of mid-2026, is reportedly gearing up for clinical trials as it moves from foundational cellular-reprogramming research toward therapeutic development.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source · 42% avg. source confidence
- FinSMEs — Altos Labs reaches $5B valuation, prepares for clinical trials42% source confidence
Dependency Map
What Altos Labs depends on below, and who depends on Altos Labs above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Altos Labs's Timeline
A sourced, dated history of Altos Labs's key moments — founding to present.
Jan 2021 · Founded with backing from Bezos, Milner and Arch Venture Partners
Altos Labs was founded to research cellular reprogramming for reversing aspects of biological aging, backed by Jeff Bezos, Yuri Milner, Arch Venture Partners founder Robert Nelson and Palantir cofounder Joe Lonsdale.
May 2026 · Reaches $5B valuation, gears up for clinical trials
Altos Labs, having raised more than $3 billion to date, reached a $5 billion valuation as of May 2026 and was reported to be preparing to move from foundational research into clinical trials.